Cancer Prevention Vaccine Trials Start This Summer

A pioneering cancer vaccine, a joint effort between the University of Oxford and Moderna, is scheduled for trials this summer.

This vaccine is designed for individuals at high risk of bowel and ovarian cancer, particularly those with Lynch syndrome. The study aims to assess its effectiveness in training the immune system to detect and destroy pre-cancerous cells, thereby preventing cancer development.

This development represents Moderna's first application of its mRNA technology in cancer prevention. Experts from Oxford believe this approach could be adapted for other cancer types in the future.

Lynch syndrome affects a significant portion of the population in England, approximately one in 300 people, many of whom are unaware they carry the condition. It substantially increases the risk of several cancers, including bowel, womb, and ovarian cancers.

The Intercept-Lynch trial is a scientific collaboration backed by Cancer Research UK. Initial phases will focus on safety, optimal dosage, and immune responses. Subsequent phases, including multiple UK centers, are anticipated to commence in 2027.

Professor David Church of Oxford University explained that the vaccine acts as an "instruction manual" for the body, enabling the immune system to recognize and attack abnormal cells before they develop into cancer. He highlighted its potential to be transformative for Lynch syndrome patients, offering broad protection across multiple cancer types.